Finding cures for children's genetic diseases


Major Achievements

1996  Cell Signalling Unit established.
2000  Began collaboration with medicinal chemist, Adam McCluskey.
2003  Identified the signalling that controls dynamin in neurons.
2004  First to report an inhibitor of dynamin and endocytosis.
2006  First to show that dynamin-dependent endocytosis controls nerve transmission.
2009  A series of publications describes development of a wide range of dynamin inhibitors, notably the Dynoles.
2010 Revealed further complexity in the signalling that controls dynamin and found that dynamin regulates long term nerve transmission changesWith Megan Chircop, were first to show dynamin II gene is a new target for cancer therapeutics.
2010 - 2012 With Adam McCluskey, reported several large studies of new dynamin inhibitors for epilepsy and cancer treatment, inhibitors now widely used in labs across the world.
2011  Toolkit of dynamin inhibitors licensed to Abcam Plc for commercial sales for researchers.
2012 Identified the signalling control point for neuron branching and development. Officially opened the first ACRF Centre for Kinomics, with Prof Adam McCluskey, to accelerate therapeutic drug discovery.
What’s Next Pre-clinical trials for dynamin inhibitors and ring stabilizers in epilepsy, kidney disease and infectious disease.